Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (271-280 of 350) with videos related to

Pageof 35
Sort By:
Leukemia|September 26, 1997
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemiaA W Bseiso, H M Kantarjian, J Q Guo, et al.
Cancer|June 15, 1991
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, C F LeMaistre, et al.
Cancer|August 15, 1988
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinosideH M Kantarjian, R S Walters, M J Keating, et al.
The Journal of Biological Chemistry|December 15, 1990
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cellsA Wedrychowski, D Seong, N Paslidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Significance of FHIT expression in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, S O'Brien, et al.
Cancer|December 18, 2001
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phaseH M Kantarjian, J Shan, T Smith, et al.
Blood|September 6, 2001
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexesC Kardinal, B Konkol, H Lin, et al.
Leukemia Research|July 21, 1998
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemiaZ Estrov, M Talpaz, S Ku, et al.
The New England Journal of Medicine|April 5, 2001
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeB J Druker, C L Sawyers, H Kantarjian, et al.
Blood Cancer Journal|August 8, 2015
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisA Pardanani, A Tefferi, C Jamieson, et al.
Pageof 35

Showing results (271-280 of 350) with videos related to

Sort By:
Pageof 35
Leukemia|September 26, 1997
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemiaA W Bseiso, H M Kantarjian, J Q Guo, et al.
Cancer|June 15, 1991
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, C F LeMaistre, et al.
Cancer|August 15, 1988
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinosideH M Kantarjian, R S Walters, M J Keating, et al.
The Journal of Biological Chemistry|December 15, 1990
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cellsA Wedrychowski, D Seong, N Paslidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Significance of FHIT expression in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, S O'Brien, et al.
Cancer|December 18, 2001
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phaseH M Kantarjian, J Shan, T Smith, et al.
Blood|September 6, 2001
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexesC Kardinal, B Konkol, H Lin, et al.
Leukemia Research|July 21, 1998
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemiaZ Estrov, M Talpaz, S Ku, et al.
The New England Journal of Medicine|April 5, 2001
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeB J Druker, C L Sawyers, H Kantarjian, et al.
Blood Cancer Journal|August 8, 2015
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisA Pardanani, A Tefferi, C Jamieson, et al.
Pageof 35